【美台醫學研究合作新里程碑】
近年來肺癌及上呼吸道癌症病率不斷上升，為美國和台灣癌症死亡率最高的癌症。2019年美台簽署了肺癌及上呼吸道癌症研究的合作協定，由 #美國國家衛生研究院、#台北榮民總醫院 和 #國立陽明交通大學共同參與此項研究計畫，並在台灣建立了#史蒂芬索拉茲國際研究實驗室。
該合作突顯出東西方肺癌及上呼吸道癌症患者的差異，並加速開發診斷、治療和預防肺癌及上呼吸道惡性腫瘤的新方法。這些惡性腫瘤每年在全世界共造成200萬人死亡。臨床試驗即將在美國國家衛生研究院臨床中心與台北榮民總醫院同時展開。美國國家衛生研究院臨床中心是世界上從事醫學研究最大的專門醫院，台北榮民總醫院也是亞洲最大、最負盛名的醫院之一。
美國在台協會很高興於9月24日在見證了這個位於台北榮民總醫院的國際實驗室正式啟用。這類型的國際科學合作不僅將造福於人類，而且還提供訓練給肺癌及上呼吸道腫瘤醫學和轉化性癌症研究人員。
The number of people diagnosed with thoracic cancer has been increasing in recent years and its mortality rate is the highest in the United States and in Taiwan. In 2019, the United States and Taiwan signed an agreement to collaborate on thoracic cancer research and establish the Stephen J. Solarz International Research Laboratory in Taiwan. This international standard laboratory will conduct research to characterize distinct features that cause thoracic cancers in Asian versus Caucasian patients and accelerate the development of novel methods to diagnose, treat, and prevent thoracic malignancies that collectively account for two million deaths a year worldwide. Clinical trials will begin simultaneously at the U.S. National Institute of Health Clinical Center, the largest hospital in the world dedicated solely to medical research, and Taipei Veterans General Hospital (TVGH), one of the largest and most prestigious hospitals in Asia, in the near future. On Friday, AIT Economic Officer Neevy Laningham participated virtually in a ceremony to launch the Stephen J. Solarz International Research Laboratory, located in TVGH. This U.S.-Taiwan collaboration will not only benefit patients but will also provide training to future researchers in thoracic oncology and translational cancer.
taiwan rate 在 Taiwan's COVID death rate climbs to 2.4%, higher than world ... 的推薦與評價
So far Taiwan has registered 286 COVID deaths, for a mortality rate of 2.4%. That's higher than the world ... ... <看更多>